Peng Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peng Zhu has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
- Bixiang Zhang
Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
17 shared publications Xiaoping Chen
Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hepat Surg, Wuhan, Hubei, Peoples R China
12 shared publicationsFeng Xia
Department of Hepatic Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology , Wuhan
11 shared publicationsBixiang Zhang
Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 shared publicationsElijah Ndhlovu
Department of Hepatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
9 shared publications- Xiaoping Chen
Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (3) , e70643
The multifaceted roles of the ACSL family in cancer: Metabolic reprogramming, ferroptosis regulation and tumour immune microenvironment remodelling
Background: Metabolic reprogramming is a key cancer hallmark, with dysregulated fatty acid metabolism critical for tumorigenesis and progression. The acyl‐CoA synthetase long‐chain (ACSL) family (ACSL1–ACSL6) catalyzes ATP‐dependent activation of long‐chain fatty acids into acyl‐CoA, a bioactive intermediate in lipid synthesis, β‐oxidation, membrane biogenesis, and signal transduction. Dysregulated ACSL expression is widespread in malignancies, but their non‐metabolic functions (ferroptosis regulation, tumor immune microenvironment remodeling) and translational potential of targeted therapies remain to be systematically summarized. Methods: This narrative review comprehensively synthesizes existing literature on the biological functions of ACSL family members in cancer. We retrieved and analyzed studies focusing on ACSL‐mediated lipid metabolic reprogramming, ferroptosis modulation, and immunomodulatory effects, with particular emphasis on isoform‐specific mechanisms and the context‐dependent roles (pro‐tumorigenic or tumor‐suppressive) of the ACSL family across different cancer types. Additionally, we summarized emerging therapeutic strategies targeting ACSL isoforms and their translational potential. Results: ACSL isoforms exert distinct context‐dependent effects:ACSL1 promotes immunosuppressive TIME via M2 macrophage polarization;ACSL3/4 have antagonistic roles in ferroptosis;ACSL5 exerts dual effects via lipid metabolism, apoptosis, and immunity;ACSL6 involves autophagy and hematological malignancies. Dysregulation correlates with tumor progression, drug resistance, and immunotherapy response, while emerging ACSL‐targeted drugs show substantial translational potential. Conclusions: The ACSL family serves as a key regulatory node integrating lipid metabolism, ferroptosis, and tumor immunity. Its isoform‐specific mechanisms and context‐dependent characteristics highlight its potential as a precise therapeutic target. Future research should focus on optimizing isoform‐selective inhibitors, clarifying their synergistic effects with existing therapies (e.g., immune checkpoint inhibitors, radiotherapy), and validating their translational efficacy through clinical trials to advance the development of innovative cancer treatment strategies.
- 17 March 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (3) , e70643
Open AccessThe multifaceted roles of the ACSL family in cancer: Metabolic reprogramming, ferroptosis regulation and tumour immune microenvironment remodelling
Background: Metabolic reprogramming is a key cancer hallmark, with dysregulated fatty acid metabolism critical for tumorigenesis and progression. The acyl‐CoA synthetase long‐chain (ACSL) family (ACSL1–ACSL6) catalyzes ATP‐dependent activation of long‐chain fatty acids into acyl‐CoA, a bioactive intermediate in lipid synthesis, β‐oxidation, membrane biogenesis, and signal transduction. Dysregulated ACSL expression is widespread in malignancies, but their non‐metabolic functions (ferroptosis regulation, tumor immune microenvironment remodeling) and translational potential of targeted therapies remain to be systematically summarized. Methods: This narrative review comprehensively synthesizes existing literature on the biological functions of ACSL family members in cancer. We retrieved and analyzed studies focusing on ACSL‐mediated lipid metabolic reprogramming, ferroptosis modulation, and immunomodulatory effects, with particular emphasis on isoform‐specific mechanisms and the context‐dependent roles (pro‐tumorigenic or tumor‐suppressive) of the ACSL family across different cancer types. Additionally, we summarized emerging therapeutic strategies targeting ACSL isoforms and their translational potential. Results: ACSL isoforms exert distinct context‐dependent effects:ACSL1 promotes immunosuppressive TIME via M2 macrophage polarization;ACSL3/4 have antagonistic roles in ferroptosis;ACSL5 exerts dual effects via lipid metabolism, apoptosis, and immunity;ACSL6 involves autophagy and hematological malignancies. Dysregulation correlates with tumor progression, drug resistance, and immunotherapy response, while emerging ACSL‐targeted drugs show substantial translational potential. Conclusions: The ACSL family serves as a key regulatory node integrating lipid metabolism, ferroptosis, and tumor immunity. Its isoform‐specific mechanisms and context‐dependent characteristics highlight its potential as a precise therapeutic target. Future research should focus on optimizing isoform‐selective inhibitors, clarifying their synergistic effects with existing therapies (e.g., immune checkpoint inhibitors, radiotherapy), and validating their translational efficacy through clinical trials to advance the development of innovative cancer treatment strategies.
- Open Access
Development and Internal Multicenter Validation of a Deep Learning Model for Predicting Post-Hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma: A Multicenter Study
Background/Objectives: Post-hepatectomy liver failure is one of the most serious complications after liver resection for hepatocellular carcinoma and is associated with high morbidity and mortality. Traditional clinical scoring systems and statistical models provide limited predictive accuracy. This study aimed to develop and internally validate a deep learning model for predicting post-hepatectomy liver failure using multicenter clinical data. Methods: A retrospective cohort of 498 patients from six centers undergoing curative-intent liver resection for hepatocellular carcinoma was analyzed. Preoperative biochemical parameters, intraoperative surgical variables, and tumor-related characteristics were incorporated into a deep neural network, with logistic regression as a baseline comparator. Data splitting was performed before preprocessing, and imputation/scaling parameters were fitted on the training set only to prevent information leakage. Discrimination was assessed using the area under the receiver operating characteristic curve (AUC) and precision–recall (PR) curves; calibration was assessed using calibration plots and Brier score; and clinical utility was assessed using decision curve analysis (DCA). A sensitivity analysis using a preoperative-only feature set (excluding intraoperative variables) was also conducted. SHapley Additive exPlanations were used to determine variable importance. Results: The deep learning model achieved AUCs of 0.914, 0.892, and 0.906 in the training, validation, and test sets, outperforming logistic regression (0.782, 0.757, and 0.773). Key predictors included ALBI and MELD scores, prothrombin time, intraoperative blood loss, and resection extent. Calibration and decision curve analysis further supported the robustness and clinical utility of the model. Conclusions: The deep learning model provides improved predictive performance for post-hepatectomy liver failure compared with logistic regression in an internally validated multicenter cohort and may support perioperative risk stratification and surgical planning.
Open AccessDevelopment and Internal Multicenter Validation of a Deep Learning Model for Predicting Post-Hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma: A Multicenter Study
Background/Objectives: Post-hepatectomy liver failure is one of the most serious complications after liver resection for hepatocellular carcinoma and is associated with high morbidity and mortality. Traditional clinical scoring systems and statistical models provide limited predictive accuracy. This study aimed to develop and internally validate a deep learning model for predicting post-hepatectomy liver failure using multicenter clinical data. Methods: A retrospective cohort of 498 patients from six centers undergoing curative-intent liver resection for hepatocellular carcinoma was analyzed. Preoperative biochemical parameters, intraoperative surgical variables, and tumor-related characteristics were incorporated into a deep neural network, with logistic regression as a baseline comparator. Data splitting was performed before preprocessing, and imputation/scaling parameters were fitted on the training set only to prevent information leakage. Discrimination was assessed using the area under the receiver operating characteristic curve (AUC) and precision–recall (PR) curves; calibration was assessed using calibration plots and Brier score; and clinical utility was assessed using decision curve analysis (DCA). A sensitivity analysis using a preoperative-only feature set (excluding intraoperative variables) was also conducted. SHapley Additive exPlanations were used to determine variable importance. Results: The deep learning model achieved AUCs of 0.914, 0.892, and 0.906 in the training, validation, and test sets, outperforming logistic regression (0.782, 0.757, and 0.773). Key predictors included ALBI and MELD scores, prothrombin time, intraoperative blood loss, and resection extent. Calibration and decision curve analysis further supported the robustness and clinical utility of the model. Conclusions: The deep learning model provides improved predictive performance for post-hepatectomy liver failure compared with logistic regression in an internally validated multicenter cohort and may support perioperative risk stratification and surgical planning.
- Open Access
- 24 February 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 47, 101153
Conversion treatment with hepatic arterial infusion of oxaliplatin, leucovorin and fluorouracil plus intravenous bevacizumab or cetuximab for initially unresectable colorectal liver metastasis: A prospective study
- 24 February 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 47, 101153
Open AccessConversion treatment with hepatic arterial infusion of oxaliplatin, leucovorin and fluorouracil plus intravenous bevacizumab or cetuximab for initially unresectable colorectal liver metastasis: A prospective study
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma
Supplementary figures and figure legends
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma
Supplementary figures and figure legends
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma
CD1d-restricted invariant natural killer T (iNKT) cells actively patrol the liver and possess valuable antitumor potential. However, clinical trials evaluating administration of iNKT cell–specific agonist α-galactosylceramide (α-GalCer) have failed to achieve obvious tumor regression. Improving the efficacy of iNKT cell–based immunotherapy requires a better understanding of the factors restraining the clinical benefits. In the context of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we found circulating and hepatic iNKT cells were hyperactivated but demonstrated imbalances in ratio and defective α-GalCer responsiveness. Exogenous IL2 helped to expand residual α-GalCer–responsive clones with reduced T-cell receptor diversity. However, transcriptome-wide analysis revealed activation of the senescence-associated secretory phenotype and dampened cytotoxicity in iNKT cells, weakening their immune surveillance capacity. The senescent status of iNKT cells from the patients was further illustrated by cell-cycle arrest, impaired telomere maintenance, perturbed calcium transport-related biological processes, and altered metabolism. Lipidomic profiling revealed the accumulation of long-chain acylcarnitines (LCAC) and aberrant lipid metabolism in HCC tissue. Exogenous LCACs, especially palmitoyl-carnitine and stearoyl-carnitine, inhibited iNKT cell expansion and promoted senescence. Collectively, our results provide deeper insights into iNKT cell dysregulation and identify a cell senescence–associated challenge for iNKT cell–based immunotherapy in HBV-related HCC. The mechanistic links between iNKT cell senescence and accumulated LCACs suggest new targets for anti-HCC immunotherapies.Significance:Patients with HBV-related HCC exhibit a cell senescence–associated dysregulation of invariant natural killer cells that is related to altered lipid metabolism and accumulated LCACs in tumor tissue.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma
CD1d-restricted invariant natural killer T (iNKT) cells actively patrol the liver and possess valuable antitumor potential. However, clinical trials evaluating administration of iNKT cell–specific agonist α-galactosylceramide (α-GalCer) have failed to achieve obvious tumor regression. Improving the efficacy of iNKT cell–based immunotherapy requires a better understanding of the factors restraining the clinical benefits. In the context of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we found circulating and hepatic iNKT cells were hyperactivated but demonstrated imbalances in ratio and defective α-GalCer responsiveness. Exogenous IL2 helped to expand residual α-GalCer–responsive clones with reduced T-cell receptor diversity. However, transcriptome-wide analysis revealed activation of the senescence-associated secretory phenotype and dampened cytotoxicity in iNKT cells, weakening their immune surveillance capacity. The senescent status of iNKT cells from the patients was further illustrated by cell-cycle arrest, impaired telomere maintenance, perturbed calcium transport-related biological processes, and altered metabolism. Lipidomic profiling revealed the accumulation of long-chain acylcarnitines (LCAC) and aberrant lipid metabolism in HCC tissue. Exogenous LCACs, especially palmitoyl-carnitine and stearoyl-carnitine, inhibited iNKT cell expansion and promoted senescence. Collectively, our results provide deeper insights into iNKT cell dysregulation and identify a cell senescence–associated challenge for iNKT cell–based immunotherapy in HBV-related HCC. The mechanistic links between iNKT cell senescence and accumulated LCACs suggest new targets for anti-HCC immunotherapies.Significance:Patients with HBV-related HCC exhibit a cell senescence–associated dysregulation of invariant natural killer cells that is related to altered lipid metabolism and accumulated LCACs in tumor tissue.
- Open Access
- 30 October 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (6)
Risk factors for hepatocellular carcinoma rupture: multicentre retrospective study
Background: Hepatocellular carcinoma (HCC) rupture is a life-threatening complication associated with poor prognosis. This study comprehensively analysed risk factors for HCC rupture and developed a predictive model supplemented by machine learning models for early risk identification and clinical decision-making. Methods: This retrospective study analysed patients with and without HCC rupture from tertiary centres in China between January 2016 and June 2019. Propensity score matching (PSM) was used to reduce baseline differences between the rupture and non-rupture groups. Random forest and deep learning models were developed to enhance predictive accuracy and interpret variable importance. Model performance was evaluated using metrics such as precision, recall, and the F1 score across training, validation, and test cohorts. Results: Among the 5952 HCC patients, the median follow-up duration was 48.6 months. Key risk factors for HCC rupture identified in this study include cirrhosis, protrusion ratio, and tumour maximum length. The CAPTure nomogram, constructed based on these predictors, yielded area under the curve (AUC) values of 0.857, 0.824, and 0.840 in the training, validation, and test cohorts, respectively. In the test cohort, the random forest and deep learning models achieved AUCs of 0.870 and 0.872, respectively. Conclusion: This study provides a comprehensive analysis of risk factors for HCC rupture and introduces the CAPTure model as a practical and accurate tool for clinical use. By integrating traditional and machine learning approaches, the findings of this study offer robust methods for early risk assessment, resource optimization, and improved management of HCC rupture.
- 30 October 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (6)
Open AccessRisk factors for hepatocellular carcinoma rupture: multicentre retrospective study
Background: Hepatocellular carcinoma (HCC) rupture is a life-threatening complication associated with poor prognosis. This study comprehensively analysed risk factors for HCC rupture and developed a predictive model supplemented by machine learning models for early risk identification and clinical decision-making. Methods: This retrospective study analysed patients with and without HCC rupture from tertiary centres in China between January 2016 and June 2019. Propensity score matching (PSM) was used to reduce baseline differences between the rupture and non-rupture groups. Random forest and deep learning models were developed to enhance predictive accuracy and interpret variable importance. Model performance was evaluated using metrics such as precision, recall, and the F1 score across training, validation, and test cohorts. Results: Among the 5952 HCC patients, the median follow-up duration was 48.6 months. Key risk factors for HCC rupture identified in this study include cirrhosis, protrusion ratio, and tumour maximum length. The CAPTure nomogram, constructed based on these predictors, yielded area under the curve (AUC) values of 0.857, 0.824, and 0.840 in the training, validation, and test cohorts, respectively. In the test cohort, the random forest and deep learning models achieved AUCs of 0.870 and 0.872, respectively. Conclusion: This study provides a comprehensive analysis of risk factors for HCC rupture and introduces the CAPTure model as a practical and accurate tool for clinical use. By integrating traditional and machine learning approaches, the findings of this study offer robust methods for early risk assessment, resource optimization, and improved management of HCC rupture.
- Open Access
- 22 October 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 89, 103579
Feasibility and safety of remote robotic hepatectomy: a prospective single-arm study with MP1000 system in China
- 22 October 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 89, 103579
Open AccessFeasibility and safety of remote robotic hepatectomy: a prospective single-arm study with MP1000 system in China
- Open Access
- 10 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 9027
VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization
Dysregulation of MYC proto-oncogene, bHLH transcription factor (MYC) represents a common yet mechanistically unresolved driver of hepatocellular carcinoma (HCC). While MYC remains an elusive therapeutic target, developing strategies to promote its degradation emerges as a promising alternative approach. Here we show that vaccinia-related kinase 2 (VRK2) functions as a direct MYC-interacting kinase that stabilizes the oncoprotein through phosphorylation at Serine (Ser)281/293. This phosphorylation enables VRK2 to compete with the Skp1-Cullin-F-box protein complex containing FBXO24 (SCF-FBXO24) E3 ligase, thereby blocking MYC polyubiquitination and proteasomal degradation. The stabilized MYC-VRK2 complex amplifies transcriptional activation of protumorigenic programs, including the immune checkpoint programmed cell death ligand 1 (PD-L1) and VRK2 itself, establishing a self-reinforcing oncogenic circuit. Therapeutic inhibition of VRK2 in HCC models reduces MYC protein levels, suppresses tumor progression, and synergizes with anti- programmed cell death-1 (PD-1) immunotherapy. Our results reveal VRK2-mediated stabilization of MYC as a critical nexus linking hepatocarcinogenesis to immune evasion, proposing VRK2 kinase inhibition as a mechanism-based therapeutic strategy for MYC-driven HCC.
- 10 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 9027
Open AccessVRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization
Dysregulation of MYC proto-oncogene, bHLH transcription factor (MYC) represents a common yet mechanistically unresolved driver of hepatocellular carcinoma (HCC). While MYC remains an elusive therapeutic target, developing strategies to promote its degradation emerges as a promising alternative approach. Here we show that vaccinia-related kinase 2 (VRK2) functions as a direct MYC-interacting kinase that stabilizes the oncoprotein through phosphorylation at Serine (Ser)281/293. This phosphorylation enables VRK2 to compete with the Skp1-Cullin-F-box protein complex containing FBXO24 (SCF-FBXO24) E3 ligase, thereby blocking MYC polyubiquitination and proteasomal degradation. The stabilized MYC-VRK2 complex amplifies transcriptional activation of protumorigenic programs, including the immune checkpoint programmed cell death ligand 1 (PD-L1) and VRK2 itself, establishing a self-reinforcing oncogenic circuit. Therapeutic inhibition of VRK2 in HCC models reduces MYC protein levels, suppresses tumor progression, and synergizes with anti- programmed cell death-1 (PD-1) immunotherapy. Our results reveal VRK2-mediated stabilization of MYC as a critical nexus linking hepatocarcinogenesis to immune evasion, proposing VRK2 kinase inhibition as a mechanism-based therapeutic strategy for MYC-driven HCC.
- 10 September 2025
- Published by Springer Nature in Science China Life Sciences
- Vol. 69 (2) , 611-621
A novel pathologic scoring system for predicting postoperative recurrence in BCLC stage 0-A hepatocellular carcinoma patients: a nationwide multicenter study
This study aimed to develop and validate a novel pathological scoring system, the MSE score (microvascular invasion, satellite foci, Edmondson-Steiner grade), for predicting postoperative recurrence in hepatocellular carcinoma (HCC) patients at BCLC stage 0-A following liver resection. The MSE score was compared to the established microvascular invasion/satellitosis (mVI/S) scoring system, which combines microvascular invasion and satellite nodules, both of which are significant predictors of aggressive recurrence and mortality. A total of 3,338 patients from 28 centers, who underwent curative liver resection between January 2017 and January 2020, were included. These patients were divided into a training cohort (n=2,337) and a validation cohort (n=1,001). Univariate and multivariate Cox regression models, along with Kaplan-Meier survival analysis, receiver operating characteristic (ROC) curves, and random forest modeling, were used to assess recurrence factors and compare predictive performance. The results showed that the MSE score had superior discriminatory power compared to mVI/S in predicting recurrence and overall survival. Kaplan-Meier analysis indicated a significantly better separation of low- and high-risk groups with the MSE score (Pvs. mVI/S OR=1.847 (1.105–3.470)). SHAP analysis highlighted that the MSE score was more significant than mVI/S. The MSE score also outperformed traditional BCLC staging, TNM staging, and preoperative serum AFP levels in predicting recurrence. In conclusion, the MSE score provides reliable predictions for postoperative aggressive recurrence and survival in BCLC stage 0-A HCC, offering superior risk stratification compared to mVI/S and promising utility in guiding postoperative management.
- 10 September 2025
- Published by Springer Nature in Science China Life Sciences
- Vol. 69 (2) , 611-621
A novel pathologic scoring system for predicting postoperative recurrence in BCLC stage 0-A hepatocellular carcinoma patients: a nationwide multicenter study
This study aimed to develop and validate a novel pathological scoring system, the MSE score (microvascular invasion, satellite foci, Edmondson-Steiner grade), for predicting postoperative recurrence in hepatocellular carcinoma (HCC) patients at BCLC stage 0-A following liver resection. The MSE score was compared to the established microvascular invasion/satellitosis (mVI/S) scoring system, which combines microvascular invasion and satellite nodules, both of which are significant predictors of aggressive recurrence and mortality. A total of 3,338 patients from 28 centers, who underwent curative liver resection between January 2017 and January 2020, were included. These patients were divided into a training cohort (n=2,337) and a validation cohort (n=1,001). Univariate and multivariate Cox regression models, along with Kaplan-Meier survival analysis, receiver operating characteristic (ROC) curves, and random forest modeling, were used to assess recurrence factors and compare predictive performance. The results showed that the MSE score had superior discriminatory power compared to mVI/S in predicting recurrence and overall survival. Kaplan-Meier analysis indicated a significantly better separation of low- and high-risk groups with the MSE score (Pvs. mVI/S OR=1.847 (1.105–3.470)). SHAP analysis highlighted that the MSE score was more significant than mVI/S. The MSE score also outperformed traditional BCLC staging, TNM staging, and preoperative serum AFP levels in predicting recurrence. In conclusion, the MSE score provides reliable predictions for postoperative aggressive recurrence and survival in BCLC stage 0-A HCC, offering superior risk stratification compared to mVI/S and promising utility in guiding postoperative management.
- Open Access
- 29 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Liver transplant-facilitated CD161+Vα7.2+ MAIT cell recovery demonstrates clinical benefits in hepatic failure patients
Mucosal-associated invariant T (MAIT) cells exert multifaceted effects such as anti-microbial activity, tissue repair, and pro-fibrotic effects across various disease settings. Nonetheless, their role in liver injury and hemostasis remains debated. Here, we report a significant depletion and functional dysregulation of MAIT cells, which is associated with disease severity and accumulated bile acids in HBV-infected patients with varying degree of liver injury. Liver transplantation facilitates a gradual recovery of recipient-originated MAIT cells. Transcriptome analysis reveals enhanced MAIT cell activation, while TCR mining demonstrates clonotype overlap between circulating and hepatic MAIT cells during significant liver injury. TCR-activated MAIT cells from transplant recipients display higher protective capacity but reduced pathological potential than those from liver failure patients. Compromised recovery of MAIT cells is linked to post-transplantation complications, whereas prompt recovery predicates favorable clinical outcome. These findings underscore the intricate interplay between MAIT cells and the hepatic environment, highlighting MAIT cells as potential therapeutic targets and sensitive predictors for clinical outcome in individuals experiencing liver failure and post liver transplantation.
- 29 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessLiver transplant-facilitated CD161+Vα7.2+ MAIT cell recovery demonstrates clinical benefits in hepatic failure patients
Mucosal-associated invariant T (MAIT) cells exert multifaceted effects such as anti-microbial activity, tissue repair, and pro-fibrotic effects across various disease settings. Nonetheless, their role in liver injury and hemostasis remains debated. Here, we report a significant depletion and functional dysregulation of MAIT cells, which is associated with disease severity and accumulated bile acids in HBV-infected patients with varying degree of liver injury. Liver transplantation facilitates a gradual recovery of recipient-originated MAIT cells. Transcriptome analysis reveals enhanced MAIT cell activation, while TCR mining demonstrates clonotype overlap between circulating and hepatic MAIT cells during significant liver injury. TCR-activated MAIT cells from transplant recipients display higher protective capacity but reduced pathological potential than those from liver failure patients. Compromised recovery of MAIT cells is linked to post-transplantation complications, whereas prompt recovery predicates favorable clinical outcome. These findings underscore the intricate interplay between MAIT cells and the hepatic environment, highlighting MAIT cells as potential therapeutic targets and sensitive predictors for clinical outcome in individuals experiencing liver failure and post liver transplantation.